---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-117913"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:29:20.796145+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO settles GSK sublicense fee dispute for $10M

## Summary
- Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.
- Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.
- Company retains existing allocation methodology for future sublicense fee payments to GSK.
- Dispute covered sublicense fees and royalties on amounts received from sublicensees.

## SEC filing metadata
- accession: 0001193125-26-117913
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/rgnx-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-117913
- JSON: https://secwatch.observer/filing/0001193125-26-117913.json
- Plain text: https://secwatch.observer/filing/0001193125-26-117913.txt

## Source-grounded claims
- claim_id: c12e231e4a45f79d0d62d320d32a74dcb40a4903
  claim: REGENXBIO Inc. entered into Settlement and Release Agreement with GlaxoSmithKline LLC valued at $10.0 million (effective 2026-03-18).
  evidence_excerpt: On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.